Antagonists at the neurokinin receptors - Recent patent literature

IDrugs

Volumn 6, Issue 8, 2003, Pages 758-772

  Giardina, Giuseppe A M ^a   Gagliardi, Stefania ^a   Martinelli, Marisa ^a  

^a NiKem Research   (Italy)

Author keywords

Combined neurokinen receptor antagonists; NK1 receptor; NK2 receptor; NK3 receptor

Indexed keywords

3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [1 [2 [4 BENZOYL 2 (3,4 DIFLUOROPHENYL) 2 MORPHOLINYL]ETHYL] 4 PHENYL 4 PIPERIDINYL] 1,1 DIMETHYLUREA; 5 AMINOVALERYLSUBSTANCE P [7-11][9 PROLINE 10 (N METHYLLEUCINE)]; 6 MORPHOLINYL 4 TOLYLPYRIDINE DERIVATIVE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CASOPITANT; CISPLATIN; DIAZASPIROUNDECANONE DERIVATIVE; EZLOPITANT; NEPADUTANT; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; OSANETANT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; R 673; SAREDUTANT; SB 235375; SB 400238; SB 414240; SPIRO COMPOUND; SUBSTANCE P; SUBSTANCE P DERIVATIVE; TACHYKININ RECEPTOR ANTAGONIST; TAK 637; TALNETANT; UK 224671; UK 290795; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESTIPITANT; VOFOPITANT; ZD 2249; ZD 4974; ZD 6021;

ANXIETY DISORDER; CANCER; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL MODIFICATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; HUMAN; MENTAL DISEASE; NAUSEA AND VOMITING; NONHUMAN; PAIN; PATENT; PROSTATE HYPERTROPHY; PUBLICATION; REVIEW; SCIENTIFIC LITERATURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG COMBINATIONS; HUMANS; PEPTIDES; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; RECEPTORS, NEUROKININ-3;

EID: 0043195904     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. 1 receptor antagonists for the control of chemotherapy-induced nausea and vomiting. Exp Opin Ther Patents (2001) 11(12):1837-1847.
2. 1 receptor) antagonists. Curr Opin Invest Drugs (2002) 3(2):257-261.
3. 1 receptor) antagonists. Can J Physiol Pharmacol (2002) 80(5):489-494.
4. Lieb K, Treffurth Y, Berger M, Fiebich BL: Substance P and affective disorders: New treatment opportunities by neurokinin 1 receptor antagonists? Neuropsychobiology (2002) 45(Suppl 1):2-6.
5. Stout SC, Owens MJ, Nemeroff CB: Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol (2001) 41:877-906.
6. Sorbera LA, Castaner J, Bayes M, Silvestre J: Aprepitant and L-758298. Drugs Future (2002) 27:211-222.
7. Roche Holding AG: December 2001 - Investor presentation. Company Presentation (2001) November 21.
8. Hale JH, Mills SG, MacCoss M, Finke PE, Cascieri MA, Sadowski S, Ber E, Chicchi GG, Kurtz M, Metzger J, Eiermann G et al. Structural optimisation affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-o xo-1,2,4-triazol-5-yl)methylmorpholine, a potent orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem (1998) 41(23):4607-4614. This paper discloses aprepitant and its outstanding pharmacological profile that allowed Merck to enter it into clinical developmental for emesis and depression.
9. Merck & Co Inc: FDA grants Priority Review for EMEND, Merck's investigational medicine for prevention of chemotherapy-induced nausea and vomiting. Press Release (2002) December 09.
10. 1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther (2002) 300(3):925-931.
11. Okano S, Nagaya H, Inatomi N: Effects of TAK-637, a neurokinin-1 (NK) receptor antagonist, on stress-induced defecation in mongolian gerbils. Jpn J Pharmacol (2001) 85:220.
12. Rupniak NMJ, Carlson EC, Harrison T, Oates B, Seward E, Owen S, De Felipe C, Hunt S, Wheeldon A: Pharmacological blockade or genetic deletion of substance P (NK-1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology (2000) 39(8):1413-1421.
13. Lowe JA III, Drozda SE, Snider RM, Longo KP, Zorn SH, Morrone J, Jackson ER, McLean S, Bryce DK, Bordner J, Nagahisa A et al. The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-azabicyclo[2.2.2]o ctan-3-amine as a novel, nonpeptide substance P antagonist. J Med Chem (1992) 35(14):2591-2600.
14. 1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound. Bioorg Med Chem Lett (1996) 6(9):1015-1020.
15. Evangelista S: Ezlopitant. Curr Opin Invest Drugs (2001) 2(10);1441-1443.
16. Callahan MJ: Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol (2002) 35(Suppl 1):58-67.
17. Research & development: The Menarini Group, Pomezia, Italy. http://www.menarini.com/english/ricerca_sviluppo/nepadutant.htm
18. Emonds-Alt X, Vilain P, Goulaouic P, Proietto V, Van Broeck D, Advenier C, Naline E, Neliat G, Le Fur G, Breliere JC: A potent and selective non-peptide antagonist of the neurokinin A (NK-2) receptor. Life Sci (1992) 50(15):PL101-PL106.
19. Sanofi-Synthélabo: Financial Analysts Meeting: Information meeting - 18 & 19 February, 2003. Company Presentation (2003) February 18-19.
20. Middleton D: Balancing potency and oral bioavailability. The design and profile of neurokinin-2-antagonists for the treatment of urinary urge incontinence. 223rd ACS Meeting, Orlando, FL, USA (2002):MEDI 137.
21. Beaumont K, Harper A, Smith DA, Bennett J: The role of P-glycoprotein in determining the oral absorption and clearance of the NK-2 antagonist, UK-224671. Eur J Pharm Sci (2002) 12(1):41-50.
22. Beaumont K: Turning peptidic G-protein coupled receptor ligands into drugs. SMi Conf - G-Protein Coupled Receptors (2003) 30 30 June - 01 July.
23. Bernstein PR, Aharony D, Albert JS, Andisik D, Barthlow HG, Bialecki RA, Davenport T, Dendinas RF, Dembofsky BT, Koether G, Kosmider BJ et al. Discovery of novel, orally active dual NK-1/NK-2 antagonists. Bioorg Med Chem Lett (2001) 11(20):2769-2773.
24. Rumsey WL, Aharony B, Bialecki RA, Abbott BM, Barthlow HG, Caccese R, Ghanekar S, Lengel D, McCarthy M, Wenrich B, Undem B et al. Pharmacological characterization of ZD6021: A novel, orally active antagonist of the tachykinin receptors. J Pharmacol Exp Ther (2001) 298(1):307-315.
25. 2 receptor affinity and selectivity.
26. Emonds-Alt X, Bichon D, Ducoux JP, Heaulme M, Milouz B, Poncelet M, Proieto V, Van Broeck D, Vilain P, Neliat G, Soubrie P et al: SR 142,801, the first potent non-peptide antagonist of the tachykinin NK-3 receptor. Life Sci (1995) 56 (1):PL27-PL32.
27. Giardina GAM, Sarau HM, Farina C, Medhurst AD, Grugni M, Foley JJ, Raveglia LF, Schmidt DB, Rigolio R, Vassallo M, Vecchietti V et al. 2-Phenyl-4-quinolinecarboxamides: A novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor. J Med Chem (1996) 39(12):2281-2284.
28. Giardina GAM, Raveglia LF, Grugni M, Sarau HM, Farina C, Medhurst AD, Graziani D, Schmidt DB, Rigolio R, Luttmann M, Cavagnera S et al. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412). J Med Chem (1999) 42(6):1053-1065.
29. Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GAM et al: Nonpeptide tachykinin receptor antagonists. I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective NK-3 receptor antagonist. J Pharmacol Exp Ther (1997) 281(3):1303-1311.
30. GlaxoSmithKline plc: Product development pipeline. Company Publication (2003) February 12.
31. 2-selective antagonists.
32. Hay DWP, Giardina GAM, Griswold DE, Underwood D, Kotzer C, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB et al: Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric-acid-induced cough and airways hyperreactivity in guinea pigs. J Pharmacol Exp Ther (2002) 300(1):314-323.
33. Milkhaus Laboratory Inc (Lieberman AD, McMichel J): Methods of treatment comprising administration of substance P. WO-00243748 (2002).
34. Dabur Research Foundation (Burman AC, Prasad S, Mukherhee R, Jaggi M, Singh AT): Substance P analogs for the treatment of cancer. WO-00210194 (2002).
35. F Hoffman-La Roche AG (Stadler H): Pyrimidine derivatives. WO-00242280 (2002).
36. F Hoffman-La Roche AG (Hoffmann, T, Schnider P, Stadler H): 4-Phenyl-pyridine derivatives as neurokinin-1 receptor antagonists. WO-00208232 (2002).
37. F Hoffman-La Roche AG (Godel T, Hoffmann T, Schnider P, Stadler H): 4-Phenyl-pyridine derivatives as neurokinin-1 receptor antagonists. WO-00216324 (2002).
38. F Hoffman-La Roche AG (Hoffmann-Emery F, Scalone M, Spurr P): Process for the manufacture of phenylacetic acid derivatives. WO-02079134 (2002).
39. 1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives. WO-00206236 (2002).
40. F Hoffman-La Roche AG (Buser S, Ford APDW, Hoffmann T, Lenz B, Sleight AJ, Vankan P): Use of NK-1 receptor antagonists against benign prostatic hyperplasia. WO-02085458 (2002).
41. F Hoffman-La Roche AG (Kuentz M, Roethlisberger D): Self emulsifying lipid matrix (selm). WO-00247663 (2002).
42. F Hoffman-La Roche AG (Kolczewski S, Roever S, Schnider P): Piperidine derivatives as neurokinin 1 antagonists. WO-02062784 (2002).
43. F Hoffman-La Roche AG (Cai HY, Dillon MP, Galley G, Goergler A, Kolcewsky S, Muszynski-Barsy DM): 1-Oxa-3,9-diaza-spiro[5.5]-undecan-2-ones derivatives and their use as antagonist of the neurokinin receptor. WO-02092604 (2002).
44. Merck Sharp & Dohme Ltd (Castro Pineiro JL, Dinnell K, Elliott JM, Hollingworth GJ, Shaw DE, Swain CJ): Gem-disubstituted cyclohexane derivatives and their use as therapeutic agents. WO-02102372 (2002).
45. Merck Sharp & Dohme Ltd (Huscroft IT, Kulagowski JJ, Raubo PA): Azabicyclic spiroether derivatives and their use as therapeutic agents. US-06479486 (2002).
46. Merck Sharp & Dohme Ltd (Castro Piniero JL, Owen SN, Seward EM, Swain CJ, Williams BJ): Tetrahydropyran derivatives as NK-1 receptor antagonists. (2002).
47. Merck Sharp & Dohme Ltd (Castro Piniero JL, Rabuo PA, Swain CJ): Tetrahydropyran derivatives as neurokinin receptor agonists. WO-02057250 (2002).
48. Merck Sharp & Dohme Ltd (Owen SN, Swain CJ, Williams BJ): Tetrahydrofuran derivatives and their use as NK-1 antagonists. WO-00224673 (2002).
49. Merck & Co Inc (Finke PE, Meurer LC, Mills SG, Maccoss M, Qi H): Zwitterionic tachykinin receptor antagonists. WO-00224629 (2002).
50. Merck & Co Inc (Huskey SW, Chiu SL): Mammalian metabolites of a tachykinin receptor antagonist. WO-00234699 (2002).
51. Merck & Co Inc (Dorn CP, Finke PE, Hale JJ, MacCoss M, Mills SG, Shah SK, Chambers MS, Harrison T, Ladduwahetty T, Williams BJ:) Morpholine and thiomorpholine tachykinin receptor antagonists. US-05719147 (1998).
52. Takeda Chemical Industries Ltd (Doi T, Ban T) Preventives/remedies for emotional disorders. WO-00226260 (2002).
53. Takeda Chemical Industries Ltd (Ikeura Y, Hashimoto T, Tarui N, Kamo I, Shirai J:) Tricyclic heterocyclic compound, process for producing the same, and use. WO-02074771 (2002).
54. 1 receptor.
55. Glaxo Wellcome plc (Alvaro G:) [1,4]-Diazepane-1-carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists. WO-02081457 (2002).
56. Glaxo Wellcome plc (Pentassuglia G:) Piperazine derivatives as tachykinin antagonists. WO-02081461 (2002).
57. Glaxo Wellcome plc (Alvaro G, Di Fabio R, Maragni P, Tampieri M, Tranquilli ME:) Chemical compounds. WO-00232867 (2002).
58. Solvay Pharmaceuticals GmbH (Jasserand D, Schon U, Sann H, Bruckner R, Eeckhout C:) N-Triazolylmethyl-piperazine derivatives as neurokinin receptor-antagonists. EP-01176144 (2002).
59. Boehringer Ingelheim Pharma KG (Dollinger H, Esser F, Jung B, Schromm K, Speck G:) Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds. WO-00232865 (2002).
60. Boehringer Ingelheim Pharma KG (Dollinger H, Esser F, Jung B, Schnorrenberg G, Schromm K, Speck G:) (4-Acylaminopiperidin-1-yl)acetamides as neurokinin antagonists. WO-00232866 (2002).
61. Boehringer Ingelheim Pharma KG (Esser F, Schnorrenberg G, Schromm K, Dollinger H, Jung B, Speck G:) Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds. WO-09732865 (1997).
62. Boehringer Ingelheim Pharma KG (Schnorrenberg G, Dollinger H, Esser F, Briem H, Jung B, Speck G): Aryl glycinamide derivatives, method of producing these substances and pharmaceutical compositions containing such compounds. WO-09632386 (1996).
63. Pfizer Product Inc (Neill BT, Saltarelli MD:) Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists. EP-01172106 (2002).
64. Menarini Ricerche SpA (Guidi A. Pasqui F, Altamura M, Maggi CA:) Basic compounds containing tertiary amides with activity on tachykinin receptors, and pharmaceutical compositions containing them. WO-00220437 (2002).
65. Nippon Kayaku Co Ltd (Adzuma S, Yamamoto T, Amayama Y, Ishida A:) Novel naphthyridine derivatives or their pharmacologically acceptable salts. JP-14088081 (2002).
66. Nippon Kayaku Co Ltd (Satoh Y, Tsuda M, Nagai M, Yamazaki H:) Process for producing novel naphthyridine derivatives. US-06433174 (2002).
67. AstraZeneca AB (Bernstein P:) Cyclized benzamide neurokinin antagonists for use in therapy. WO-00226724 (2002).
68. AstraZeneca AB (Bernstein P:) Novel N-(2-phenyl-3-aminopropyl)naphthamides. WO-00212168 (2002).
69. AstraZeneca AB (Shenvi AB:) Compounds. WO-02051807 (2002).
70. Sanofi-Synthélabo (Emonds-Alt X, Proietto V:) Novel piperidine carboxamide derivatives, method for preparing same and pharmaceutical compositions containing same. WO-02094821 (2002).
71. GlaxoSmithKline SpA (Farina C, Gagliardi S, Giardina GAM, Grugni M, Martinelli M, Nadler GMMG:) Quinolino derivatives as NK-3 and NK-2 antagonists. WO-00238547 (2002).
72. GlaxoSmithKline SpA (Farina C, Giardina GAM, Grugni M, Nadler GMMG:) Quinolone-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists. WO-00238548 (2002).
73. GlaxoSmithKline SpA (Farina C, Giardina GAM, Grugni M, Nadler GMMG:) Novel compounds. WO-00243734 (2002).
74. GlaxoSmithKline SpA (Farina C, Giardina GAM, Grugni M, Nadler GMMG:) Novel compounds. WO-00244154 (2002).
75. GlaxoSmithKline SpA (Farina C, Gagliardi S, Giardina GAM, Grugni M, Nadler GMMG, Martinelli M:) Quinoline derivatives as NK-3 antagonists. WO-00244165 (2002).
76. GlaxoSmithKline SpA (Farina C, Gagliardi S, Giardina GAM, Martinelli M:) 3-Substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists. WO-02083664 (2002).
77. GlaxoSmithKline SpA (Farina C, Gagliardi S, Giardina GAM, Martinelli M:) Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists. WO-02083663 (2002).
78. GlaxoSmithKline SpA (Farina C, Giardina GAM, Grugni M, Perugini L:) Novel compounds. WO-02083645 (2002).
79. SmithKline Beecham SpA (Farina C, Giardina GAM, Grugni M:) Quinoline 4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists. WO-00031037 (2000).
80. SmithKline Beecham SpA/SmithKline Beecham Laboratoires Pharmaceutiques (Farina C, Giardina GAM, Grugni M, Nadler GMMG:) Quinoline derivatives as NK-2 and NK-3 receptor ligands. WO-0031038 (2000).
81. 3 receptor antagonists.
82. Fujisawa Pharmaceutical Co Ltd (Take K, Kasahara C, Shigenaga S, Azami H, Eikyu Y, Nakai K, Morita M:) 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin antagonists. WO-02055518 (2002).
83. Ortho-McNeil Pharmaceutical Inc (Kordik CP, Reitz AB, Coats SJ, Luo C, Pan K, Parker MH:) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders. WO-00240466 (2002).
84. SmithKline Beecham Corporation (Dillon SB, Tal-Singer R:) Novel use. WO-00240023 (2002).
85. SmithKline Beecham SpA (Giardina GAM, Grugni M, Raveglia LF, Farina C:) Quinoline derivatives. WO-09721680 (1997).
86. SmithKline Beecham plc (Machin P:) Novel pharmaceutical use of quinoline derivatives. WO-00213825 (2002).
87. University of Rochester (Guttuso TJ:) Method for treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist. WO-00195904 (2001).
88. Schering Corporation (Leach MW, Berardi MR, Mirro EJ, Sinha D, Pachter J, Cartwright ME, Reichard GA:) Use of neurokinin receptor antagonists to treat androgen-dependent diseases. WO-02089802 (2002).
89. SmithKline Beecham Corporation (Murphy DJ, Wier PJ, Giardina GAM:) Anti-androgens and methods for treating disease. WO-00043008 (2000).
90. SmithKline Beecham Corporation (Koretke TW, Bhatt KH:) Novel solid dispersion compositions. WO-00195939 (2001).
91. Takeda Chemical Industries Ltd (Doi T, Hashimoto T, Kamo I:) Combination drugs. WO-02051440 (2002).
92. 1 receptor antagonists. WO-02069944 (2002).
93. Pfizer Products Inc (Lowe JA, McLean S, Sobolov-Janes SB:) Combination for treating depression and anxiety containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist. EP-01192952 (2002).
94. 1 receptor antagonist and a CNS penetrant NK-1 receptor antagonist. EP-01186318 (2002).
95. McGill University (Henry JL, Cahill CM, Yashpal K:) Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof. WO-00213799 (2002).